Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:25 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 649–672 of 5,568 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Combination Agent Clear all

Conditions: Gout, Hyperuricemia
Interventions: Tranilast, Febuxostat, Combination - Tranilast and Febuxostat; Drug
Lead sponsor: Nuon Therapeutics, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 3
States / cities: Honolulu, Hawaii • Evansville, Indiana • Dallas, Texas

Conditions: Breast Cancer, Invasive Breast Cancer, Unresectable Breast Carcinoma, Locally Advanced Breast Cancer, Metastatic Breast Cancer, Inflammatory Breast Cancer, Triple Negative Breast Cancer (TNBC), Hormone Receptor/Growth Factor Receptor-Negative Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Negative Breast Carcinoma
Interventions: Onvansertib, Paclitaxel; Drug
Lead sponsor: Antonio Giordano, MD; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 3
States / cities: Boston, Massachusetts

Conditions: E Cigarette Use, Cessation, Tobacco, Cessation, Nicotine
Interventions: Nicotine Replacement Therapies, Brief Behavioral Counseling; Drug · Behavioral
Lead sponsor: West Virginia University; Other
Eligibility: 21 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: Greenville, North Carolina • Morgantown, West Virginia

Conditions: Obsessive-Compulsive Disorder
Interventions: 3,4-Methyl enedioxy methamphetamine, Methamphetamine, Cognitive Behavioral Therapy (CBT); Drug · Behavioral
Lead sponsor: Carolyn Rodriguez; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Hemostasis
Interventions: Fibrin Pad, SURGICEL™; Drug · Device
Lead sponsor: Ethicon, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 141 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 11
States / cities: Birmingham, Alabama • Jacksonville, Florida • Miami, Florida + 6 more

Conditions: Prostatic Neoplasms
Interventions: Docetaxel (TAXOTERE®) Chemotherapy, Leuprolide acetate ( ELIGARD®) Hormonal Therapy; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 228 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Chemotherapy-induced Peripheral Neuropathy
Interventions: Memantine XR-pregabalin combination therapy; Drug
Lead sponsor: Saint John's Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Santa Monica, California

Conditions: Metastatic Breast Cancer
Interventions: Trastuzumab deruxtecan, Durvalumab, Paclitaxel, Capivasertib, Anastrozole, Fulvestrant, Capecitabine; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 9
States / cities: Commack, New York • Harrison, New York • New York, New York + 5 more

Conditions: Hepatitis, HIV/AIDS
Interventions: Boceprevir, Peg-Interferon-alfa 2B, Ribavirin; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Bethesda, Maryland

Conditions: Acute Leukemia, Lymphoblastic Leukemia, Lymphoblastic Lymphoma
Interventions: LP-118, Ponatinib, Vincristine, Dexamethasone, Methotrexate; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 2
States / cities: Chicago, Illinois • Rochester, New York

Conditions: Hematological Malignancies
Interventions: Magrolimab, Azacitidine; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 258 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 26
States / cities: Duarte, California • La Jolla, California • Los Angeles, California + 20 more

Conditions: Healthy
Interventions: Shigella sonnei 53G; Biological
Lead sponsor: PATH; Other
Eligibility: 18 Years to 49 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Solid Tumor, Adult, Squamous Cell Carcinoma of Head and Neck, Colorectal Adenocarcinoma, Metastatic Solid Tumor, Recurrent Solid Tumor, Head and Neck Cancer
Interventions: NT219, NT219 and ERBITUX® - Dose Escalation, NT219 and ERBITUX® - Expansion; Drug
Lead sponsor: TyrNovo Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 7
States / cities: Encinitas, California • Los Angeles, California • San Diego, California + 4 more

Conditions: Non Small Cell Lung Cancer Metastatic
Interventions: Acasunlimab, Pembrolizumab; Biological
Lead sponsor: Genmab; Industry
Eligibility: 18 Years and older
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 6
States / cities: Santa Rosa, California • Fort Myers, Florida • St. Petersburg, Florida + 3 more

Conditions: Heroin Dependence, Morphine Dependence, Substance Withdrawal Syndrome
Interventions: Buprenorphine/naloxone; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 15 Years and older
Enrollment: 341 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2002
U.S. locations: 7
States / cities: Berkeley, California • Oxnard, California • Indianapolis, Indiana + 4 more

Conditions: HIV Infections
Interventions: Interleukin-2 SA, HAART; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 9
States / cities: Birmingham, Alabama • Davis, California • Los Angeles, California + 5 more

Conditions: Multiple Myeloma
Interventions: Oprozomib, Dexamethasone; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 10
States / cities: Los Angeles, California • Tampa, Florida • Westwood, Kansas + 6 more

Conditions: HER2-positive Early-stage Breast Cancer
Interventions: Trastuzumab, Pertuzumab, Docetaxel, Carboplatin; Drug
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years to 90 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 7
States / cities: Elizabeth, New Jersey • Hamilton, New Jersey • Long Branch, New Jersey + 4 more

Conditions: Stroke
Interventions: Actuated Virtual Keyboard (AVK) system, Occupational Therapy (OT); Behavioral
Lead sponsor: North Carolina State University; Other
Eligibility: 21 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Raleigh, North Carolina

Conditions: Lymphoma, Large Cell, Lymphoma, Non-Hodgkin
Interventions: Doxorubicin, Cotrimoxazole, Carboplatin, Ifosfamide, Dexamethasone, Prednisone, Vincristine, Cytarabine, Methotrexate, Etoposide, Cyclophosphamide, Vinblastine, Stem cell transplant,, Radiation Therapy; Drug · Procedure · Radiation
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Up to 18 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2001
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Hypertension
Interventions: LCZ696, Valsartan, AHU377, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 1,334 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 38
States / cities: Birmingham, Alabama • Muscle Shoals, Alabama • Chandler, Arizona + 30 more

Conditions: Acute Myeloid Leukemia
Interventions: Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Cytarabine, Daunorubicin, Decitabine and Cedazuridine, Venetoclax; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 7
States / cities: Birmingham, Alabama • New Haven, Connecticut • Buffalo, New York + 3 more

Conditions: Asthma
Interventions: budesonide/formoterol, fluticasone/salmeterol, mometasone/formoterol, Prednisone; Drug
Lead sponsor: Gelb, Arthur F., M.D.; Individual
Eligibility: 10 Years to 95 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2027
U.S. locations: 1
States / cities: Lakewood, California

Conditions: Gastro-enteropancreatic Neuroendocrine Tumor, Neuroendocrine Tumors
Interventions: Lutathera, Azedra; Drug
Lead sponsor: David Bushnell; Other
Eligibility: 18 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Iowa City, Iowa

Search by objective public record fields.

Study of Tranilast Alone or in Combination With Febuxostat in Patients With Hyperuricemia

Onvansertib + Paclitaxel In TNBC

Evaluation of Dependence and Nicotine Replacement Therapy-Supported Cessation Efforts Among Regular Electronic Cigarette Use

MDMA-Assisted CBT for OCD (MDMA-CBT4OCD Study)

The Fibrin Patch Soft Tissue Study

Adjuvant Leuprolide With or Without Docetaxel in High Risk Prostate Cancer After Radical Prostatectomy

Memantine XR and Pregabalin for Chemotherapy-Induced Peripheral Neuropathy

A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer

Boceprevir Drug Combination for Hepatitis C Treatment in People With and Without HIV

A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL)

Magrolimab Monotherapy or Magrolimab in Combination With Azacitidine in Participants With Hematological Malignancies

Dose-Finding Study of Lyophilized Shigella Sonnei 53G Challenge Strain

A Study to Evaluate NT219 Alone and in Combination with ERBITUX® (Cetuximab) in Adults with Advanced Solid Tumors and Head and Neck Cancer

Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung Cancer

Buprenorphine/Naloxone Versus Clonidine for Outpatient Opiate Detoxification - 1

Safety and Efficacy of BAY 50-4798 in Patients With HIV Infection

Phase 1b/2, Multicenter, Open-label Study of Oprozomib and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma

Optimize Neoadjuvant Therapy in HER2-Positive Early-Stage Breast Cancer

Finger Movement Training After Stroke

Large Cell Lymphoma Pilot Study III

Efficacy and Safety of LCZ696A in Patients With Essential Hypertension

Testing Oral Decitabine and Cedazuridine (ASTX727) in Combination With Venetoclax for Higher-Risk Acute Myeloid Leukemia Patients

Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma

A Clinical Trial Evaluating the Safety of Combining Lutathera(R) and Azedra(R) to Treat Mid-gut Neuroendocrine Tumors